<DOC>
	<DOC>NCT00076401</DOC>
	<brief_summary>The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.</brief_summary>
	<brief_title>A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>At least 18 years old Refractory or relapsed CLL ECOG performance status score of 0, 1, or 2 Each patient must sign a studyspecific informed consent form Laboratory values of: Platelet count &lt;30,000/uL AST or ALT &gt;2 x the upper limit of normal (ULN) Total bilirubin &gt;2 x ULN Creatinine &gt;2.0 mg/dL Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment Women who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>CLL</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>relapsed chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Motexafin gadolinium</keyword>
	<keyword>Chronic leukemia</keyword>
	<keyword>Lymphocytic leukemia, chronic</keyword>
</DOC>